Navigation Links
Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
Date:9/24/2007

EAST SETAUKET, N.Y., Sept. 24 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) today announced the trading of its common shares on the Over-The-Counter Bulletin Board under the Symbol LIXT.

Commenting on this important milestone, President and CEO John S. Kovach, M.D. stated, "We believe that being a publicly traded company will enable us to pursue funding opportunities that were not available to us as a private company. Having access to the capital markets is important at this stage of Lixte's development. Over the coming months our strategy is to continue with our research under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), while at the same time exploring other cancer research opportunities that Lixte is developing independently."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. (Lixte) is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, the company develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the discovery of a new biomarker for brain cancers by collaborators at NIH, the company is developing new drugs for the treatment of glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain cancer in adults and, to a much lesser extent, in children.

GBM occurs annually in 20,000 to 25,000 adults in the United States and in a comparable number of individuals in Europe. At present, there is no curative treatment known for this disease. Standard treatment involves surgery, radiation and the use of one or more chemotherapeutic agents at the time of initial treatment. At relapse, which occurs in essentially all patients, the present standard treatment is a drug, Temozolomide, that is associated with a modest increase
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Olympics of biotechnology has international flavor
2. Making Wisconsin the biotechnology leader
3. Let the olympics of biotechnology in the Midwest begin!
4. The mushrooming of biotechnology in the U.S.
5. 42 days until the 2006 Olympics of Biotechnology in Chicago
6. Third coast of biotechnology makes strong showing at VC conference
7. State wants to encourage industrial biotechnology
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. First graduates boon to Wisconsin biotechnology
10. Americas Third Coast nurtures biotechnology
11. Florida: Investing Heavily in Biotechnology - Governor uses state funds to attract large biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
... , June 25 Ruedi Waeger , Ph.D., former president ... of Directors, was honored with the Robert W. Reilly Leadership award June ... , , , ... Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership qualities ...
... Beardsworth Consulting Group, Inc. announces the appointments of ... Robert W. Malone , M.D. as the company,s Medical Director, Vaccines. ... Dr. Alison Martin ... of clinical research experience.  She joins Beardsworth from the National Cancer Institute ...
... HOPKINTON, Mass. , June 25 Caliper Life ... and services for drug discovery and life sciences research, hosted its ... 9 and 10. This thought-leadership conference is focused on sharing ... process, leading to the next generation of breakthrough diagnostics and therapies. ...
Cached Biology Technology:Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association 2Alison Martin, MD and Robert W. Malone, MD Join Beardsworth 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 3
(Date:7/24/2014)... a low vision specialist at The University of Texas ... been awarded a grant to help Harris County residents ... or surgery. , Even with corrective lenses, many people ... there are a variety of low vision devices, such ... their vision loss. , Iyer is using the three-year, ...
(Date:7/24/2014)... week for an all-day public forum on a $1.7 ... to dredge toxic sediment from an eight-mile stretch of ... the plan, which proposes removing 4.3 million cubic yards ... one of the largest cleanups in the agency,s history. ... , "We need to ensure the future well-being of ...
(Date:7/24/2014)... the United States, wildland managers often utilize the silvicultural ... (ladder fuels). These cuttings and other post-logging debris ... in order to dispose of the material. To improve ... cover all or part of the debris pile with ... in order to keep water out. A recent study ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... of Energy,s Advanced Research Projects Agency (ARPA-E) has awarded ... Carolina State University to support research into the creation ... in high-temperature environments. "Most biofuels, such as ethanol ... plants through photosynthesis. Our project would cut out the ...
... A system that allows precise targeting of radiotherapy using ... dose of radiation they administered to lung and liver cancers ... the 2nd European Lung Cancer Conference. "With this study ... have a precise system that can give information at any ...
... is available in Spanish . , Agricultural ... Research Center in Burns, Ore., are taking a careful ... high desert rangelands. Cattle share this habitat with ... the showy commotion they create during mating season. But ...
Cached Biology News:NC State wins ARPA-E grant to study extremophile production of biofuels 2ARS scientists study effects of grazing on grouse habitat 2
AedestaTM Animal Organ/Tissue Perfusion Soln....
ANTI FLAG EP CL VEC...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: